<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285165</url>
  </required_header>
  <id_info>
    <org_study_id>17200002</org_study_id>
    <nct_id>NCT03285165</nct_id>
  </id_info>
  <brief_title>Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients</brief_title>
  <acronym>DEXSEDATION</acronym>
  <official_title>Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serial transcranial Doppler (TCD) exams in healthy volunteers and in animal models showed a
      strong linear relationship between middle cerebral artery (MCA) flow velocity (FV) and
      dexmedetomidine infusion. The concomitant elevation of pulsatility index (PI) indicates
      vasoconstriction of the cerebral vasculature as the most profound underlying mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available clinical evidence on the use of dexmedetomidine sedation in neurosurgical and
      neurocritical care is limited and no definite conclusion can be drawn. There is a need for
      The use of dexmedetomidine might be a useful adjunct in clinical situations when the increase
      in CBF could be detrimental such as vasogenic cerebral edema (i.e., TBI, large brain tumors).
      However, dexmedetomidine sedation is questionable in patients with subarachnoid hemorrhage
      and acute stroke, since the associate drop in arterial pressure could worsen the coexisting
      increase in circulating catecholamines and massive sympathetic outflow. Further high-quality
      RCTs to evaluate the use of dexmedetomidine as a sedative agent both in general ICU patients
      and in patients with TBI.

      Transcranial Doppler (TCD) is a simple noninvasive bedside tool to assess the cerebral blood
      flow pattern. The new development of transcranial color Doppler with angle correction option
      helps to improve the sensitivity of test results. TCD can assess the evolution of CBF
      alterations and possibly cerebral autoregulation performance and ICP estimation in patients
      presenting with cerebral pathology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>this study will be accomplished to investigate the effect of dexmedetomidine sedation on the cerebral blood flow in intubated mechanically ventilated trauma patients with and without traumatic brain injury, in comparison with propofol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Middle cerebral artery flow velocity</measure>
    <time_frame>24 hours</time_frame>
    <description>1. Right and left middle cerebral artery (MCA) will be measured via trans-temporal window and the depth of insinuation will be between 30-60 mm with the subject's head in neutral position. Mean values of simultaneously measured invasive blood pressure recordings and the outer envelope of time averaged MCA flow velocity (FV) recordings during ten consecutive cardiac cycles</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>DEX I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2-0.7 mcg/kg/h dexmedetomedine infusion.</intervention_name>
    <description>patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.</description>
    <arm_group_label>DEX I</arm_group_label>
    <arm_group_label>DEX II</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-70 mcg/kg/h propofol infusion.</intervention_name>
    <description>Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.</description>
    <arm_group_label>Propofol I</arm_group_label>
    <arm_group_label>Propofol II</arm_group_label>
    <other_name>Deprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult trauma patients (18-50 years old, ASA I-II).

          -  With and without mild TBI.

          -  Mild traumatic brain injury will include; brain edema, brain contusion, fracture base,
             fissure fracture and depressed fracture.

          -  The severity of traumatic brain injury will be defined as mild based on basal Glasgow
             Coma Scale and basal Computerized tomography scanning.

          -  Requirements of endotracheal intubation, mechanical ventilation and light to moderate
             sedation because of associated abdominal or chest traumatic injuries.

          -  The sedation needed should of an estimated duration not less than 24h.

          -  Baseline hemodynamic parameters within the normal range.

          -  Baseline middle cerebral artery flow velocity within the normal range.

        Exclusion Criteria:

          -  Severe traumatic brain injury, subarachnoid hemorrhage and Intra-cerebral hemorrhage.

          -  Spinal cord injury.

          -  Hemodynamically unstable patients and patients on inotropes.

          -  Patients who have a cardiac pacemaker or automatic implantable cardioverter
             defibrillator.

          -  Patients with hepatic or renal impairment.

          -  Pregnant females.

          -  Patients who are incarcerated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdelghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant professor in anesthesia and intensive care, faculty of medicine, Assiut university, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hala S Abdelghaffar, MD</last_name>
    <phone>01003812011</phone>
    <phone_ext>+2088</phone_ext>
    <email>hallasaad@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omnia H Thabet, MBBCH</last_name>
    <phone>01095029249</phone>
    <phone_ext>+2088</phone_ext>
    <email>dr_omnia_h@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut university main hospital, Trauma ICU</name>
      <address>
        <city>Assiut</city>
        <state>Assiut governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hala S Abdelghaffar, MD</last_name>
      <phone>01003812011</phone>
      <phone_ext>+2 088</phone_ext>
      <email>hallasaad@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Omnia H Thabet, MBBCH</last_name>
      <phone>01095029249</phone>
      <phone_ext>+2 088</phone_ext>
      <email>dr_omnia_h@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>Assisstant professor in anesthesia and intensive care, Faculty of medicine, Assiut university, Egypt.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

